MYGN Q3 2023 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q3 2023 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$192M+22.7% YoY

Gross Profit

$134M70.0% margin

Operating Income

-$60M-31.3% margin

Net Income

-$61M-31.9% margin

EPS (Diluted)

$-0.75

QoQ Revenue Growth

+4.6%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$40M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$466M

Stockholders' Equity

$683M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$192M	$156M	+22.7%
Gross Profit	$134M	$106M	+26.7%
Operating Income	-$60M	-$45M	-33.6%
Net Income	-$61M	-$35M	-74.6%

Geographic Segments

UNITED STATES

$172M90%

Non-US

$20M10%